CAJ | 학술논문

目前用于慢性乙型肝炎（CHB）抗病毒治疗的药物有干扰素（IFN）与核苷和核苷酸类药物（NAs）两大类。IFN在抗HBV方面虽取得了一定的效果，但抗病毒作用有限，且不良反应较大；NAs抗病毒作用强、不良反应发生率低，但也存在一些问题，如停药后易复发、随着疗程延长产生耐药的趋势增加等。因此，探索抗病毒药物的优化治疗方案，进一步提高CHB抗病毒治疗的有效性和安全性对临床医生而言具有十分重要的意义。就近年来国内外对两类药物联合或序贯治疗的研究进展进行阐述，使临床医生对抗HBV的联合或序贯治疗有更加深入的了解，为CHB患者的抗病毒治疗提供更多选择。
목전용우만성을형간염（CHB）항병독치료적약물유간우소（IFN）여핵감화핵감산류약물（NAs）량대류。IFN재항HBV방면수취득료일정적효과，단항병독작용유한，차불량반응교대；NAs항병독작용강、불량반응발생솔저，단야존재일사문제，여정약후역복발、수착료정연장산생내약적추세증가등。인차，탐색항병독약물적우화치료방안，진일보제고CHB항병독치료적유효성화안전성대림상의생이언구유십분중요적의의。취근년래국내외대량류약물연합혹서관치료적연구진전진행천술，사림상의생대항HBV적연합혹서관치료유경가심입적료해，위CHB환자적항병독치료제공경다선택。
Currently,there are two categories of antiviral drugs used for chronic hepatitis B (CHB):interferons (IFNs)and nucleos(t)ide analogues (NAs).IFNs showed lower efficacy and more adverse effects,although they achieved some anti -HBV results.NAs showed stronger antiviral activity and a lower incidence rate of adverse effects;however,there are also some problems,such as high risk of relapse after the NAs are discontinued and increased rate of drug resistance with a longer course of treatment.Therefore,it is very important for cli-nicians to investigate the optimal therapy against HBV to further improve efficacy and safety in the treatment of CHB.In this paper,the re-search on combination therapy and sequential therapy against HBV is reviewed,in the hope that clinicians may have a deeper knowledge of combination therapy and sequential therapy against HBV,so as to provide more choices for antiviral therapy of CHB patients.